In vitro inhibition of SKOV-3 cell migration as a distinctive feature of progesterone receptor membrane component

Christian Albrecht1, Volker Huck, Martin Wehling

  • 1University of Heidelberg, Clinical Pharmacology Mannheim, Maybachstr. 14, 68169 Mannheim, Germany.

Steroids
|October 16, 2012
PubMed

Insights

Progesterone receptor membrane component type 2 (PGRMC2) inhibits ovarian cancer cell migration. PGRMC2 overexpression reduced SKOV-3 cell migration, while depletion increased it, revealing its role in ovarian cancer cell mobility.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Oncology

Background:

  • Progesterone receptor membrane component type 2 (PGRMC2) is homologous to PGRMC1, which is implicated in ovarian cancer chemotherapy resistance.
  • Limited in vitro characterization exists for PGRMC2 compared to PGRMC1.
  • Understanding PGRMC2's function is crucial for ovarian cancer research.

Purpose of the Study:

  • To investigate the role of PGRMC2 in ovarian cancer cell proliferation and migration.
  • To compare the functional effects of PGRMC2 with PGRMC1 in SKOV-3 cells.

Main Methods:

  • Generated SKOV-3 cells with PGRMC1 and PGRMC2 depletion or overexpression.
  • Utilized electric cell-substrate impedance sensing (ECIS) to assess cell migration rates.
  • Performed cell viability assays and analyzed protein levels after cisplatin treatment.

Main Results:

  • PGRMC2 overexpression significantly inhibited SKOV-3 cell migration, whereas PGRMC2 depletion increased migration.
  • PGRMC1 did not affect migration in the ECIS assay.
  • No significant differences in cell viability or response to cisplatin/progesterone were observed for PGRMC2, unlike reported effects for PGRMC1.

Conclusions:

  • PGRMC2 plays a significant inhibitory role in ovarian cancer cell migration in vitro.
  • PGRMC2 protein levels decrease upon cisplatin treatment in SKOV-3 cells.
  • PGRMC2's function in ovarian cancer differs from PGRMC1, particularly regarding cell migration.

Related Concept Videos